Team:Slovenia

From 2012.igem.org

(Difference between revisions)

Latest revision as of 21:11, 26 October 2012

The Challenge

Biological drugs such as hormones, enzymes, cytokines or antibodies are increasingly used to treat different diseases. Due to systemic administration, these drugs often have adverse effects. Additionally, the high cost of biopharmaceuticals imposes a heavy burden on health systems.

We aimed to use the principles of synthetic biology to develop an advanced and safe method of in situ production of biological drugs to increase the quality of patients' lives. This system should increase compliance to therapy, decreas the number of required invasive drug administrations and enable advanced multistage therapy while local administration could reduce the side effects.

We addressed this challenge by implementing microencapsulated engineered mammalian cells that can be regulated from the outside to produce different therapeutics. This system should be effective, reliable, safe and potentially more cost-effective.

The switch Switches are the basic regulatory elements through which the state of cells can be controlled. We designed a new type of a universal bistable toggle switch for mammalian cells based on designed DNA-binding proteins. Its properties enable simultaneous introduction of several orthogonal switches and construction of complex logic devices. We found that a classic toggle switch topology is ineffective if based on TAL effectors. Our modeling explaines that the reason for this is noncooperative binding of monomeric TAL effectors to DNA. We solved this problem by introducing nonlinearity through the addition of the addition of positive feedback loops consisting of pairs of TAL activators and repressors competing for binding. This arrangement resulted, both theoretically and experimentally in mammalian cells, in functional switch that can be regulated by small molecule inducers. Read more...	Safety In order to enable safe application of engineered cells in the microencapsulation based therapy we designed three safety mechanisms to degrade the alginate capsules at the end of the therapy, terminate the therapeutic cells by induction of apoptosis and to tag any escaped cells for elimination by the host's natural killer cells. Read more...	Implementation In consultations with medical experts we tailored our therapeutic devices based on implanted microencapsulated engineered cells to the treatments of hepatitis C and ischaemic heart disease by in situ production of therapeutic protein effectors whose efficiency has already been demonstrated. In agreement with our pharmacokinetic models, this strategy could reduce side effects and improve efficiency of these therapies. Switching between production of effectors with antiviral or anti-inflammatory and tissue regenerative effect could be regulated by administrating a small molecule inducer. Read more...
Modeling Modeling was used to simulate and improve the properties of the switch and the pharmacokinetic distribution of drugs in the tissue, which is required for an effective therapy and decreased side effects. We introduced improved methods of switch simulations such as a quantitative parameter derivation and algorithmic/mixed simulation that can capture mixed regulator binding to operators. We also included into the wiki a server for online switch simulation. A pharmacokinetic model of the local delivery of therapeutics by microencapsulated cells predicted that this type of drug delivery should have reduced systemic side effects. Exhaustive modeling of the switch demonstrated that the classic genetic toggle switch arrangement is not stable without cooperativity, but it confirmed functionality and improved robustness of the our switch design with two positive feedback loops. This topology does not require cooperativity since nonlinearity is introduced by the positive feedback loop. Read more...	Society Different aspects of general medical applications of synthetic biology and our project specifically were discussed with a wide range of stakeholders, including medical professionals, patients, experts on the law and ethics of GMO use and release, scientists, the media and the general public that will all have to participate in a successful introduction of synthetic biology applications to clinical use. We attempted to organize a network of Slovenian high schools to share the excitement of synthetic biology with younger generations and to demonstrate its application in medicine and other fields. Read more...	Perspectives We anticipate that designed DNA-binding element-based transcriptional factor logic will play a very important role in the development of synthetic biology, TAL-based switches allow simultaneous introduction of multiple switches to adopt multiple cellular states with numerous medical and other applications , The safety mechanisms, including the inducible leak-free termination (prodrug), escape detection and capsule degradation components will allow implementation for different therapeutic purposes, for an effective application stable cell lines containing integrated switches with selected therapeutic effectors and safety mechanisms will have to be established, most likely by the use of human artificial chromosomes, we plan to *initiate in vivo* experiments first on ischaemia and wound healing**. Read more...

Abstract in plain english

Biological drugs are being used ever more often as advanced drugs for the treatment of numerous diseases, due to their more specific mode of action. In current therapies the biological drugs are usually distributed more or less throughout the whole body, although each function should often be restricted to a specific organ or tissue. This can cause serious side effects, requires larger dosages and consequently raises the price of therapy. Our solution to this problem was to implant cells producing biological drugs inside the very tissue where the drug is required. The drug producing cells are safely sealed inside microcapsules that prevent cells from spreading throughout the body and protect them from destruction by cells of the host immune system. We constructed a device that allows implanted cells to produce different types of drugs while switching between those production states can be controlled from the outside by a physician, depending on the stage of the disease. We designed our device specifically for the therapy of hepatitis C or heart attack. Against hepatitis C the engineered cells produce a protein with antiviral activity, whose biological activity we have tested and confirmed. After the state of the cells is switched, a protein that improves liver regeneration would be produced. For the therapy after a heart attack we designed cells to suppress local inflammation and promote formation of new blood vessels only around the affected tissue. A physician may initiate self-destruction of the therapeutic cells and capsules by an outside stimulus when the therapy is complete or at any other given time. We believe our system to be safe, effective and applicable in the real world for the therapy of different types of diseases.

Achievements in technical details

We present the first experimental implementation of a bistable toggle switch in mammalian cells based on noncooperative DNA-binding proteins as well as the first demonstration of a bistable switch based on designed DNA-binding proteins,
a bistable toggle switch based on orthogonal TAL-repressors and activators was designed and tested in mammalian cells,
mathematical modeling demonstrated improved robustness of a switch based on a positive feedback loop with respect to leaky transcription,
we introduced three safety mechanisms into microencapsulated mammalian cells:
- a tag for escaped cells enabling elimination by natural killer cells,
- a secretory alginate lyase for degradation of alginate microcapsules,
- apoptosis of therapeutic cells initiated by the addition of a prodrug.
We introduced interferon alpha and hepatocyte growth factor as an effector pair for the therapy of hepatitis C to inactivate the virus followed by the promotion of liver regeneration,
we introduced IL-1 receptor antagonist (anakinra) and vascular endothelial growth factor/platelet-derived growth factor BB as effectors for therapy of ischaemia to suppress inflammation followed by the local promotion of angiogenesis,
we deposited 89 BioBricks to the Registry and used most of them in functional devices,
we improved an existing BioBrick.

Project sponsors

Number of visits:

@@ Line 2: / Line 2: @@
 <head>
 <meta http-equiv="X-UA-Compatible" content="IE=edge" />
+<!-- back to top>
+<div style="position:fixed; bottom:45px; right:30px; width:100px; height:66px; background-color:transparent;">
+<a href="#topofthepage">
+<table style="background-color:transparent;" onclick="window.location = '#topofthepage'" class="invisible" style="height:100%;">
+<tr class="invisible" style="background-color:transparent;">
+<td class="invisible" style="background-color:transparent;" valign="center">
+<img width="100px" src ="https://static.igem.org/mediawiki/2012/1/14/Svn12_hp_btt.png"></img>
+</td></tr></table>
+</a>
+</div-->
 <style type="text/css">
@@ Line 201: / Line 213: @@
 #cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}
 #cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }
+#cssmenu ul li > ul li a table tr td span{ outline:none; display:block; position:relative; margin:0; padding:0px 0px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }
 #cssmenu, #cssmenu > ul > li > ul > li a:hover
 { 	background:#043A6B;
@@ Line 235: / Line 248: @@
 tbody .splash{ background: #fff; }
+table.newtable {background-color:transparent;}
+td.newtable, th.newtable {background-color:transparent;}
+thead.newtable{ }
+tbody .newtable{}
+a.invisible{}
@@ Line 324: / Line 342: @@
 <body>
+<a name="topofthepage" style="background-color:transparent;"></a>
 <div id="banner">
-<a style="position:absolute; top:0px; left:490px;" href="https://2012.igem.org/Main_Page"><b>iGEM 2012</b></a>
+<a style="position:absolute; top:0px; left:490px;" href="https://2012.igem.org/Main_Page"><b></b></a>
 </div>
@@ Line 348: / Line 367: @@
 		<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
 		<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
-		<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
+		<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><tr class="newtable"><td class="newtable"><span>Positive feedback loop switch</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
+    <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchControls'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><tr class="newtable"><td class="newtable"><span>Controls</span></td><td class="newtable"><img style="margin-right:-81px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 	  </ul>
 	</li>
@@ Line 356: / Line 376: @@
 		 <li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>
-		 <li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation'><span>Microcapsule degradation</span></a></li>
+     <li><a href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation"><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><tr class="newtable"><td class="newtable"><span>Microcapsule degradation</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 	  </ul>
 	</li>
@@ Line 364: / Line 384: @@
 		 <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>
+     <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationImpact'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><tr class="newtable"><td class="newtable"><span>Impact</span></td><td class="newtable"><img style="margin-right:-86px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 	  </ul>
@@ Line 371: / Line 392: @@
 	  <ul>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
-		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><span>Pharmacokinetics</span></a></li>
+     <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><tr class="newtable"><td class="newtable"><span>Pharmacokinetics</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
-		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><span>Quantitative and stability model</span></a></li>
+		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><tr class="newtable"><td class="newtable"><span>Experimental model</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
-		 <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><span>Interactive simulations</span></a></li>
+     <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Interactive simulations</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 	  </ul>
 	</li>
@@ Line 387: / Line 408: @@
 	  <ul>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
-		 <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><span>Lablog</span></a></li>
+     <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><tr class="newtable"><td class="newtable"><span>Lablog</span></td><td class="newtable"><img style="margin-right:-90px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>
 	  </ul>
@@ Line 410: / Line 431: @@
 		 <li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
+		 <li><a href='https://2012.igem.org/Team:Slovenia/TeamCollaborations'><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Collaborations</span></td><td class="newtable"><img style="margin-right:-20px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>
 		 <li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>
@@ Line 419: / Line 441: @@
 </div> <!-- end menu -->
 <div id="main">
 <br/>
+<!-- dummy link na bannerju -->
+<a href="https://2012.igem.org/Main_Page">
+<div id="dummy" style="background-color:transparent; position:absolute; left:870px; top:25px; width:115px; height:80px; z-index:100; opacity:0.0;">
+</div>
+</a>
 <!-- ikona za slovenski prevod -->
@@ Line 433: / Line 463: @@
 <strong style="font-size:120%;">The Challenge</strong><br/>
 <br />
-<p>Biological drugs such as hormones, enzymes, cytokines or antibodies are increasingly used to treat different diseases. Due to systemic administration, these drugs often have adverse effects. Additionally, the high cost of biopharmaceutials imposes a heavy burden on health systems.</p>
+<p>Biological drugs such as hormones, enzymes, cytokines or antibodies are increasingly used to treat different diseases. Due to systemic administration, these drugs often have adverse effects. Additionally, the high cost of biopharmaceuticals imposes a heavy burden on health systems.</p>
-<p>We aimed to develop a safe and cost-effective biological in situ production and delivery system for biological drugs to increase the quality of patients' lives. This system should increase compliance to the therapy, minimize the number of required invasive procedures and introduce advanced multistage therapy while local administration could reduce the side effects. </p>
+<p>We aimed to use the principles of synthetic biology to develop an advanced and safe method of <i>in situ</i> production of biological drugs to increase the quality of patients' lives. This system should increase compliance to therapy, decreas the number of required invasive drug administrations and enable advanced multistage therapy while local administration could reduce the side effects.  </p>
-<p>We addressed this challenge by implementing microencapsulated engineered mammalian cells that can be regulated from the outside to produce different therapeutics, should be reliable, cost effective and safe.</p>
+<p>We addressed this challenge by implementing microencapsulated engineered mammalian cells that can be regulated from the outside to produce different therapeutics. This system should be effective, reliable, safe and potentially more cost-effective.</p>
 </td>
 </tr>
@@ Line 458: / Line 488: @@
 <div class="ttip">
 <strong>The switch</strong>
-<p>We <b>designed a new type of bistable toggle switch for mammalian cells</b>
- based on designed DNA-binding proteins to enable simultaneous introduction of
+<p> Switches are the basic regulatory elements through which the state of cells can be controlled. We <b>designed a new type of a universal bistable toggle switch for mammalian cells</b> based on designed DNA-binding proteins. Its properties enable simultaneous introduction of several orthogonal switches and construction of complex logic devices. We found that a <b>classic toggle switch topology is ineffective</b> if based on TAL effectors. Our modeling explaines that the reason for this is  noncooperative binding of monomeric TAL effectors to DNA. We solved this problem by introducing nonlinearity through the addition of the addition of <b>positive feedback loops</b> consisting of pairs of TAL activators and repressors competing for binding. This arrangement resulted, both theoretically and experimentally in mammalian cells, in functional switch that can be regulated by small molecule inducers. <a href="https://2012.igem.org/Team:Slovenia/TheSwitch">Read more...</a></p>
- several orthogonal switches and construction of complex logic devices.
- We discovered that a <b>classical toggle switch topology was ineffective</b>
- if based on TAL effectors, because they bind to DNA non-cooperatively as monomers.
- We solved this problem by designing a switch comprised of a pair of mutual repressors
- (TAL-KRAB) coupled with a pair of activators (TAL-VP16) that form a <b>positive feedback
- loop</b>. This arrangement resulted in experimentally confirmed bistability in mammalian
- cells that can be regulated by small molecule inducers. <a href="https://2012.igem.org/Team:Slovenia/TheSwitch">Read more...</a></p>
 </div>
 </td>
@@ Line 474: / Line 497: @@
 <div class="ttip">
 <strong>Safety</strong>
-<p>In order to enable safe application of engineered cells for the microencapsulation based therapy we designed safety mechanisms to <b>degrade the alginate capsules</b> at the end of the therapy, terminate therapeutic cells by induction of apoptosis and introduction of an escape tag that <b>marks any escaped cells for elimination</b> by natural killer cells of the host. <a href="https://2012.igem.org/Team:Slovenia/SafetyMechanisms">Read more...</a></p>
+<p>In order to enable safe application of engineered cells in the microencapsulation based therapy we designed three safety mechanisms to <b>degrade the alginate capsules </b> at the end of the therapy, terminate the therapeutic cells by induction of apoptosis and to <b>tag any escaped cells for elimination</b> by the host's natural killer cells. <a href="https://2012.igem.org/Team:Slovenia/SafetyMechanisms">Read more...</a></p>
 </div>
 </td>
@@ Line 482: / Line 505: @@
 <div class="ttip">
 <strong>Implementation</strong>
-<p>We implemented the effector therapeutics for therapy of hepatitis C and ischaemic heart disease by introducing five different therapeutic proteins that could, in agreement with our pharmacokinetic models, reduce the side effects and improve the efficiency of the therapy. Switching between production of effectors with antiviral or anti-inflammatory effect and tissue regeneration could be regulated by a physician by delivery of small molecule inducers from the outside.  <a href="https://2012.igem.org/Team:Slovenia/Implementation">Read more...</a></p>
+<p>In <b>consultations with medical experts</b> we tailored our therapeutic devices based on implanted microencapsulated engineered cells to the treatments of hepatitis C and ischaemic heart disease by <i>in situ</i> <b>production of therapeutic protein effectors whose efficiency has already been demonstrated</b>. In agreement with our pharmacokinetic models, this strategy could <b>reduce side effects and improve efficiency of these therapies</b>. Switching between production of effectors with antiviral or anti-inflammatory and tissue regenerative effect could be regulated by administrating a small molecule inducer.
+  <a href="https://2012.igem.org/Team:Slovenia/Implementation">Read more...</a></p>
 </div>
 </td>
@@ Line 496: / Line 520: @@
 <div class="ttip2">
 <strong>Modeling</strong>
-<p>Exhaustive mathematical modeling demonstrated that the classical toggle genetic switch arrangement is not stable without cooperativity. At the same time, the modeling confirmed an improved robustness of the switch when using modular DNA binding element-based transcriptional regulators that formed two positive feedback loops. This topology does not require cooperativity since nonlinearity is introduced by the positive feedback loop. A pharmacokinetic model of the local delivery of therapeutics by microencapsulated cells predicted that this type of drug delivery should have reduced systemic side effects. <a href="https://2012.igem.org/Team:Slovenia/Modeling">Read more...</a></p>
+<p>Modeling was used to simulate and improve the properties of the switch and the pharmacokinetic distribution of drugs in the tissue, which is required for an effective therapy and decreased side effects. We introduced <b>improved methods of switch simulations</b> such as a quantitative parameter derivation and algorithmic/mixed simulation that can capture mixed regulator binding to operators. We also included into the wiki a server <b>for online switch simulation</b>. A pharmacokinetic model of the local delivery of therapeutics by microencapsulated cells predicted that this type of drug delivery should have reduced systemic side effects.</p><p><b>Exhaustive modeling</b> of the switch <b>demonstrated that the classic genetic toggle switch arrangement is not stable without cooperativity</b>, but it <b>confirmed functionality and improved robustness of the our switch design</b> with <b>two positive feedback loops. This topology does not require cooperativity since nonlinearity is introduced by the positive feedback loop. <a href="https://2012.igem.org/Team:Slovenia/Modeling">Read more...</a></b></p>
 </div>
 </td>
@@ Line 504: / Line 528: @@
 <div class="ttip2">
 <strong>Society</strong>
-<p>Different aspects of our project as well as the medical applications of synthetic biology were discussed with a wide range of stakeholders, including medical professionals, patients, regulators, general public, media and scientists that will have to participate in the succesfull introduction of synthetic biology applications in clinical use. We engaged a network of high schools to introduce younger generations to synthetic biology and its use in medicine as well as the broad range of its other potential uses.  <a href="https://2012.igem.org/Team:Slovenia/Society">Read more...</a></p>
+<p>Different aspects of general <b>medical applications of synthetic biology</b> and our project specifically <b>were discussed with a wide range of stakeholders, including medical professionals, patients</b>, experts on the law and ethics of GMO use and release, scientists, the media and the general public<b> that will all have to participate in a successful introduction of synthetic biology applications to clinical use</b>. We attempted to organize a <b>network of Slovenian high schools</b> to share the excitement of synthetic biology with <b>younger generations</b> and to demonstrate its application in <b>medicine and other fields</b>.  <a href="https://2012.igem.org/Team:Slovenia/Society">Read more...</a></p>
 </div>
 </td>
 <td class="splash">
-<a href="https://2012.igem.org/Team:Slovenia/SocietyEthics"><img class="pic" src="https://static.igem.org/mediawiki/2012/d/d2/Svn12_homepage_6future.png" width="300" height="300" /></a>
+<a href="https://2012.igem.org/Team:Slovenia/Implementation"><img class="pic" src="https://static.igem.org/mediawiki/2012/d/d2/Svn12_homepage_6future.png" width="300" height="300" /></a>
 <div class="ttip2">
 <strong>Perspectives</strong>
 <ul style="padding-left:30px;">
-<li> The safety device, including the termination, escape killing and degradation components will allow implementation for different therapeutic purposes,</li>
+<li> We anticipate that designed DNA-binding element-based transcriptional factor logic will play a very important role in the development of synthetic biology,</li>
-<li>we plan to establish stable cell lines, each containing an integrated switch with the selected therapeutic effectors and safety mechanisms,</li>
+<li>TAL-based switches allow simultaneous introduction of multiple switches to adopt multiple cellular states with numerous medical and other applications ,</li>
-<li>the designed orthogonal TAL-based transcriptional factor logic will allow construction of tens or hundreds of different switches and achievement of multistable states and other complex logical devices,</li>
+<li><b>The safety</b> mechanisms, <b>including the inducible leak-free termination (prodrug), escape detection and capsule degradation components will allow implementation for different therapeutic purposes</b>,</li>
-<li>We plan to initiate the first in vivo tests on ischaemia and wound healing.</li>
+<li>for an effective application <b>stable cell lines</b> containing integrated switches with selected therapeutic effectors and safety mechanisms will have to be established, most likely by the use of human artificial chromosomes,</li>
+<li>we plan to <b>initiate <i>in vivo</i> experiments</b> first <b>on ischaemia and wound healing</b>.</li>
 </ul>
-<p><a href="https://2012.igem.org/Team:Slovenia/SocietyEthics">Read more...</a></p>
+<p><a href="https://2012.igem.org/Team:Slovenia/Implementation">Read more...</a></p>
 </div>
 </td>
@@ Line 539: / Line 564: @@
 <strong style="font-size:120%;">Abstract in plain english</strong><br/>
 <br />
-<p>Biological drugs have lately been replacing chemical drugs in the treatement of numerous diseases due to their more specific nature. The current route of biological drug administration is usually intravenous or subcutaneous, which means that the drug is distributed more or less throughout the whole body, although its function should often be restricted to a specific organ or tissue. This can cause serious side effects, requires larger dosage and consequently raises the price of therapy. Our solution of this problem is to implant cells producing biological drugs inside the very tissue where the drug is required. The drug producing cells are safely sealed inside microcapsules, preventing dissemination of these cells and protecting them from destruction by the cells of the host immune system. The implanted cells are able to produce different types of drugs and switching between them can be controlled by a physician depending on the stage of the disease.  We invented a new type of switch that will allow selecting production of different biological drug combinations in the affected tissue. We have modified cells for use in the therapy of hepatitis C, where the engineered cells produce a biological drug that has antiviral activity followed by a drug that improves liver regeneration. For the therapy after a heart attack we designed cells to suppress inflammation and promote the formation of new blood vessels around the affected tissue. A physician may initiate self-destruction of the cells and capsules by an outside stimulus when the therapy is over or at any other given time. We believe our system to be safe and effective and applicable to the therapy of different types of diseases.<p>
+<p>Biological drugs are being used ever more often as advanced drugs for the treatment of numerous diseases, due to their more specific mode of action. In current therapies the biological drugs are usually distributed more or less throughout the whole body, although each function should often be restricted to a specific organ or tissue. This can cause serious side effects, requires larger dosages and consequently raises the price of therapy. Our solution to this problem was to implant cells producing biological drugs inside the very tissue where the drug is required. The drug producing cells are safely sealed inside microcapsules that prevent cells from spreading throughout the body and protect them from destruction by cells of the host immune system. We constructed a device that allows implanted cells to produce different types of drugs while switching between those production states can be controlled from the outside by a physician, depending on the stage of the disease. We designed our device specifically for the therapy of hepatitis C or heart attack. Against hepatitis C the engineered cells produce a protein with antiviral activity, whose biological activity we have tested and confirmed. After the state of the cells is switched, a protein that improves liver regeneration would be produced. For the therapy after a heart attack we designed cells to suppress local inflammation and promote formation of new blood vessels only around the affected tissue. A physician may initiate self-destruction of the therapeutic cells and capsules by an outside stimulus when the therapy is complete or at any other given time. We believe our system to be safe, effective and applicable in the real world for the therapy of different types of diseases.</p>
 </td>
@@ Line 549: / Line 574: @@
+<!-- youtube video -->
+<p>
+<table class="invisible" style="width:60%;">
+<tbody  class="invisible">
+<tr class="invisible">
+<td class="invisible">
+<iframe width="560" height="315" src="http://www.youtube.com/embed/9HBQbR42KWQ" frameborder="0" allowfullscreen></iframe>
+</td>
+</tr>
+</tbody>
+</table>
+<!-- end table-->
+<!-- youtube end -->
@@ Line 557: / Line 594: @@
 <tr class="outcome">
 <td class="outcome" style="font-size:110%;">
-<strong style="font-size:120%;">Outcome</strong><br/>
+<strong style="font-size:120%;">Achievements in technical details</strong><br/>
 <br />
-<strong>Achievements in technical details:</strong>
 <ul style="padding-left: 30px;">
-<li> this is the first experimental implementation of a bistable toggle switch based on noncooperative DNA-binding proteins and the first bistable switch based on designed DNA-binding proteins,</li>
+<li>We present the first experimental implementation of a bistable toggle switch in mammalian cells based on noncooperative DNA-binding proteins as well as the first demonstration of a bistable switch based on designed DNA-binding proteins,</li>
-<li>we designed and tested a bistable toggle switch for mammalian cells based on orthogonal TAL-repressors and activators,</li>
+<li>a bistable toggle switch based on orthogonal TAL-repressors and activators was designed and tested in mammalian cells,</li>
-<li> modeling demonstrated improved robustness of a switch based on a positive feedback loop, with respect to leaky transcription,</li>
+<li>mathematical modeling demonstrated improved robustness of a switch based on a positive feedback loop with respect to leaky transcription,</li>
 <li>we introduced three safety mechanisms into microencapsulated mammalian cells:
 	<ul class="circle" style="padding-left: 50px;">
-	<li>an escape tag for cell elimination by natural killer cells,</li>
+	<li>a tag for escaped cells enabling elimination by natural killer cells,</li>
 	<li>a secretory alginate lyase for degradation of alginate microcapsules,</li>
-	<li>induction of apoptosis of therapeutic cells by the introduction of a prodrug,</li>
+	<li>apoptosis of therapeutic cells initiated by the addition of a prodrug.</li>
 	</ul>
 	</li>
-<li>we introduced interferon alpha/hepatocyte growth factor as an effector pair for the therapy of hepatitis C to inactivate the virus followed by the promotion of liver regeneration, </li>
+<li>We introduced interferon alpha and hepatocyte growth factor as an effector pair for the therapy of hepatitis C to inactivate the virus followed by the promotion of liver regeneration, </li>
-<li>  we introduced anakinra/vascular endothelial growth factor:platelet-derived growth factor as effectors for therapy of ischaemia to suppress inflammation followed by angiogenesis.</li>
+<li>  we introduced IL-1 receptor antagonist (anakinra) and vascular endothelial growth factor/platelet-derived growth factor BB as effectors for therapy of ischaemia to suppress inflammation followed by the local promotion of angiogenesis,</li>
-<li>we deposited 90 BioBricks to the Registry, most of them used in functional devices,</li>
+<li>we deposited 89 BioBricks to the Registry and used most of them in functional devices,</li>
 <li>we improved an existing BioBrick.</li>
 </ul>
@@ Line 588: / Line 624: @@
 <tbody  class="invisible">
 		<tr class="invisible">
-                <td class="invisible">
-<a href="http://enfist.si/"><img src="https://static.igem.org/mediawiki/2012/1/18/Svn12_sponsors_enfist.png"></img></a><br/><br/><br/>
+<!--- column 1--->
-<a href="http://www.sklad-kadri.si/"><img src="https://static.igem.org/mediawiki/2012/b/b6/Svn12_sponsors_javniskladrs.png"></img></a><br/><br/><br/>
+<td class="invisible" valign="top" width="300px">
-<a href="http://www.lek.si/"><img src="https://static.igem.org/mediawiki/2012/f/f1/Svn12_sponsors_lek.jpg"></a></img><br/><br/><br/>
+<a href="http://enfist.si/"><img width="100%" src="https://static.igem.org/mediawiki/2012/1/18/Svn12_sponsors_enfist.png"></img></a><br/><br/><br/>
-<a href="http://www.kemomed.si/"><img src="https://static.igem.org/mediawiki/2012/d/da/Svn12_sponsors_kemomed.jpg" ></a></img><br/><br/><br/>
+<a href="http://www.lek.si/"><img  width="80%" src="https://static.igem.org/mediawiki/2012/f/f1/Svn12_sponsors_lek.jpg"></a></img><br/><br/><br/>
-<a href="http://www.roche.si/"><img src="https://static.igem.org/mediawiki/2012/3/3b/Svn12_sponsors_roche.jpg"></a></img><br/><br/><br/>
+<a href="http://www.kemomed.si/"><img width="50%" src="https://static.igem.org/mediawiki/2012/d/da/Svn12_sponsors_kemomed.jpg" ></a></img><br/><br/><br/>
-<a href="http://www.osir.si/"><img src="https://static.igem.org/mediawiki/2012/7/75/Svn12_sponsors_osir.jpeg"></a></img><br/><br/><br/>
+<a href="http://www.roche.si/"><img width="50%" src="https://static.igem.org/mediawiki/2012/3/3b/Svn12_sponsors_roche.jpg"></a></img><br/><br/><br/>
-<a href="http://www.adria.si/"><img src="https://static.igem.org/mediawiki/2012/9/9f/Svn12_sponsors_adria.png"></a></img>
+<a href="http://www.osir.si/"><img width="40%" src="https://static.igem.org/mediawiki/2012/7/75/Svn12_sponsors_osir.jpeg"></a></img><br/><br/><br/>
-                </td>
+<a href="http://www.adria.si/"><img width="40%" src="https://static.igem.org/mediawiki/2012/9/9f/Svn12_sponsors_adria.png"></a></img>
-                <td class="invisible">
-<a href="http://www.ki.si/"><img src="https://static.igem.org/mediawiki/2012/7/7e/Svn12_sponsors_ki.png" ></a></img><br/><br/><br/>
+</td>
-<a href="http://www.arrs.gov.si"><img src="https://static.igem.org/mediawiki/2012/d/dc/Svn12_sponsors_arrs.gif"></img><br/><br/><br/>
-<a href="http://www.fri.uni-lj.si/"><img src="https://static.igem.org/mediawiki/2012/6/6b/Svn12_sponsors_fri.png" ></img></a><br/><br/><br/>
+<!--- column 2--->
-<a href="http://www.krka.si/"><img src="https://static.igem.org/mediawiki/2012/8/84/Svn12_sponsors_krka.png"></img></a><br/><br/><br/>
+<td class="invisible"  valign="top" width="300px">
-<a href="http://www.omega.si/"><img src="https://static.igem.org/mediawiki/2012/4/45/Svn12_sponsors_omega.png"></img></a><br/><br/><br/><br/>
+<a href="http://www.ki.si/"><img width="100%" src="https://static.igem.org/mediawiki/2012/7/7e/Svn12_sponsors_ki.png" ></a></img><br/><br/><br/>
-<a href="http://eu.idtdna.com/"><img src="https://static.igem.org/mediawiki/2012/9/9e/Svn12_sponsors_itdna.png"></img></a><br/><br/><br/>
+<a href="http://www.fri.uni-lj.si/"><img width="80%" src="https://static.igem.org/mediawiki/2012/6/6b/Svn12_sponsors_fri.png" ></img></a><br/><br/><br/>
-<a href="http://www.chemass.si/"><img src="https://static.igem.org/mediawiki/2012/5/5f/Svn12_sponsors_chemass.PNG"></img></a>
+<a href="http://www.mf.uni-lj.si/"><img width="60%" src="https://static.igem.org/mediawiki/2012/a/a1/Svn12_sponsors_mf.PNG"/></a><br/><br/><br/>
-                </td>
+<a href="http://www.krka.si/"><img width="50%" src="https://static.igem.org/mediawiki/2012/8/84/Svn12_sponsors_krka.png"></img></a><br/><br/><br/>
-                </tr>
+<a href="http://www.erasynbio.eu/"><img width="60%" src="https://static.igem.org/mediawiki/2012/f/ff/Svn12_logo_eransynbio.jpg"></a></img><br/><br/><br/>
+<a href="http://www.omega.si/"><img width="65%" src="https://static.igem.org/mediawiki/2012/4/45/Svn12_sponsors_omega.png"></img></a><br/><br/><br/><br/>
+<a href="http://eu.idtdna.com/"><img width="60%" src="https://static.igem.org/mediawiki/2012/9/9e/Svn12_sponsors_itdna.png"></img></a><br/><br/><br/>
+</td>
+<!--- column 3--->
+<td class="invisible"  valign="top" width="300px">
+<a href="http://www.sklad-kadri.si/"><img width="80%" src="https://static.igem.org/mediawiki/2012/b/b6/Svn12_sponsors_javniskladrs.png"></img></a><br/><br/><br/>
+<a href="http://www.arrs.gov.si"><img width="95%" src="https://static.igem.org/mediawiki/2012/d/dc/Svn12_sponsors_arrs.gif"></img><br/><br/><br/>
+<a href="http://www.bf.uni-lj.si/"><img width="65%" src="https://static.igem.org/mediawiki/2012/9/97/Svn12_logo_biotech.jpg"></a></img><br/><br/><br/>
+<a href="http://www.fkkt.uni-lj.si/en/"><img  width="70%" src="https://static.igem.org/mediawiki/2012/5/59/Svn12_logo_fkkt.jpg"></img></a><br/><br/><br/>
+<a href="http://www.eimv.si/"><img width="70%" src="https://static.igem.org/mediawiki/2012/5/5f/Svn12_logo_eimv.jpg"></img></a><br/><br/><br/><br/>
+<a href="http://www.chemass.si/"><img width="60%" src="https://static.igem.org/mediawiki/2012/5/5f/Svn12_sponsors_chemass.PNG"></img></a>
+</td>
 </tbody>
 </table>
@@ Line 616: / Line 669: @@
+<!-- Start of StatCounter Code for Default Guide -->
+<b>Number of visits:
+<script type="text/javascript">
+var sc_project=8388055;
+var sc_invisible=0;
+var sc_security="76d66c5e";
+var sc_text=2;
+</script>
+<script type="text/javascript"
+src="http://www.statcounter.com/counter/counter.js"></script>
+<noscript><div class="statcounter"><a title="free hit
+counter" href="http://statcounter.com/free-hit-counter/"
+target="_blank"><img class="statcounter"
+src="http://c.statcounter.com/8388055/0/76d66c5e/0/"
+alt="free hit counter"></a></div></noscript>
+</b>
+<!-- End of StatCounter Code for Default Guide -->
 </div>
 <!--</div>-->